From the publishers of JADPRO

Multiple Myeloma Resource Center

Advertisement

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Last Updated: Monday, March 24, 2025

BCMA-directed therapies, including CAR-T cell therapy and bispecific antibodies, show promising efficacy in patients with multiple myeloma refractory to daratumumab. These treatments demonstrate high response rates and improved survival outcomes. Further research is needed to establish best practices in this setting.

Cancer Medicine
Advertisement
News & Literature Highlights
Advertisement
Advertisement